Teva wins FDA approval for monthly schizophrenia injection Weltruza
Teva has received FDA approval for once monthly injectable schizophrenia drug Weltruza.
The announcement sent Teva shares gaining in premarket.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.cnbc.com — the content belongs to CNBC.